We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Qutenza

News List

Grünenthal, Averitas Announce FDA Approval of QUTENZA for Neuropathic Pain americanpharmaceuticalreview
July 29, 2020
Grünenthal announced its U.S. subsidiary Averitas Pharma, received U.S. Food and Drug Administration (FDA) approval for QUTENZA® (capsaicin) 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet...
Averitas Announces sNDA Filing for QUTENZA for Neuropathic Pain americanpharmaceuticalreview
December 20, 2019
Averitas Pharma announced the supplemental New Drug Application (sNDA) for QUTENZA for the treatment of neuropathic pain associated with diabetic peripheral neuropathy ...
Grunenthal establishes commercial footprint in the US biospectrumasia
November 19, 2018
Averitas Pharma will be commercialising the pain patch Qutenza (8% capsaicin) for Grunenthal in the US.